You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


triple negative breast cancer x

Lab worker with samples

Triple-negative breast cancer (TNBC) is very aggressive and fast-growing, with nearly no targeted therapies available today. TNBC represents 10 to 20 percent of diagnosed breast cancers and is more likely to affect younger people and those with a BRCA1 gene mutation.

To understand triple negative breast cancer, we first have to understand how breast cancer is classified. Breast tumors are broadly classified into three major subtypes: estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2 receptor positive or triple negative.

Immunotherapy Extends Lives for Patients with Advanced Triple Negative Breast Cancer

Triple negative breast cancer is an aggressive disease with a high likelihood of spreading to other tissues, a process called metastasis. TNBC is primarily treated with chemotherapy.

Triple negative breast cancer (TNBC) is so named because TNBC cells lack the three common breast tumor markers:  estrogen receptor, progesterone receptor and the HER2 protein.  Unlike breast cancers with these markers, there are currently no FDA-approved targeted therapies for TNBC.

Triple negative breast cancer (TNBC) comprises 15-20 percent of all breast cancers, but few treatment options exist outside of chemotherapy.

Using only a blood test, researchers have identified a biomarker that can predict prognosis in patients with metastatic triple negative breast cancer (mTNBC).

Most clinical studies collect blood, tumor samples, or other tissue from participants. While this data is important for the study at hand, the samples may help future studies as well.

Dr. Leisha Emens is at the Johns Hopkins Kimmel Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy.